01552nam 2200397 450 991070748680332120160811083738.0(CKB)5470000002464657(OCoLC)956500470(OCoLC)995470000002464657(EXLCZ)99547000000246465720160811d2016 ua 0engurmn|||||||||rdacontentrdamediardacarrierFDA is issuing more postmarketing requirements, but challenges with oversight persist[Washington, D.C.] :Department of Health and Human Services, Office of Inspector General,2016.1 online resource (26 pages) illustrationsTitle from title screen (viewed Aug 9, 2016)."July 2016.""OEI-01-14-00390."Includes bibliographical references.Food and Drug Administration is issuing more postmarketing requirements, but challenges with oversight persistFDA is issuing more postmarketing requirements, but challenges with oversight persistDrugsUnited StatesTestingManagementClinical trialsGovernment policyUnited StatesDrugsTestingManagement.Clinical trialsGovernment policyGPOGPOBOOK9910707486803321FDA is issuing more postmarketing requirements, but challenges with oversight persist3304909UNINA